# Acquipharma

> Acquipharma is a VC fund backing Finance, Medical and Health Care. See 5 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Total investments: 5
- Last investment: Sep 2025
- Lead investor: 20%
- Last updated: Aug 2026

Acquipharma is a VC fund focused on Finance and Medical. Acquipharma is headed by Oppel Greeff, a medical doctor and a former executive with publicly traded Quintiles Transnational Corp.

## Round sizes

| Stage | Round size |
| --- | --- |
| Series B | $7.5M–$18M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Finance | 1 | 20% |
| Medical | 1 | 20% |
| Health Care | 1 | 20% |
| Life Science | 1 | 20% |
| Biotechnology | 1 | 20% |

9 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 1 | 20% |
| Series B | 1 | 20% |
| Funding Round | 1 | 20% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| India | 1 | 20% |
| United States | 1 | 20% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Burl Concepts | Burl Concepts is a San Diego-based medical device start-up that manufactures portable ultrasound device to detect strokes in the field. It was founded in order to bring a portable and affordable pre-hospital stroke detection solution to millions of at-risk people worldwide.Fueled by an interdisciplinary exchange of ideas between the naturalsciences and engineering disciplines, the company seeks to bring academic institutions and industrial partners together to meet today’s challenges in global medical care. The first product from BURL Concepts is the SONAS portable, battery-powered ultrasound device designed for the non-invasive, transcranial diagnosis of major strokes.Founded in 2013, Burl Concepts is based on the research of Thilo Hoelscher, a neurologist who previously served as a professor at UC San Diego, where he founded the UCSD Brain Ultrasound Research Laboratory. | $4.5M |  | Sep 02, 2025 |  |
| BUGWORKS Research | BUGWORKS is a drug discovery company that aims to discover novel pharmaceutical assets for combating Antimicrobial Resistance (AMR). The company was founded in 2014 and is based in Bangalore, India. | $18M | Series B | Feb 09, 2022 |  |
| BUGWORKS Research | BUGWORKS is a drug discovery company that aims to discover novel pharmaceutical assets for combating Antimicrobial Resistance (AMR). The company was founded in 2014 and is based in Bangalore, India. | $7.5M | Series B | Apr 22, 2020 |  |
| BUGWORKS Research | BUGWORKS is a drug discovery company that aims to discover novel pharmaceutical assets for combating Antimicrobial Resistance (AMR). The company was founded in 2014 and is based in Bangalore, India. | $9M | Series A | Aug 13, 2018 |  |
| Burl Concepts | Burl Concepts is a San Diego-based medical device start-up that manufactures portable ultrasound device to detect strokes in the field. It was founded in order to bring a portable and affordable pre-hospital stroke detection solution to millions of at-risk people worldwide.Fueled by an interdisciplinary exchange of ideas between the naturalsciences and engineering disciplines, the company seeks to bring academic institutions and industrial partners together to meet today’s challenges in global medical care. The first product from BURL Concepts is the SONAS portable, battery-powered ultrasound device designed for the non-invasive, transcranial diagnosis of major strokes.Founded in 2013, Burl Concepts is based on the research of Thilo Hoelscher, a neurologist who previously served as a professor at UC San Diego, where he founded the UCSD Brain Ultrasound Research Laboratory. | $3M |  | Oct 04, 2016 |  |

5 of 5 investments shown.

## Co-investors
- [UTEC - The University of Tokyo Edge Capital Partners](https://shizune.co/investors/profile/utec) — VC Fund, 6 deals together
- [3one4 Capital](https://shizune.co/investors/profile/3one4) — VC Fund, 2 deals together
- [Global Brain Corporation](https://shizune.co/investors/profile/global-brain-corporation) — VC Fund, 2 deals together
- [Featherlite](https://shizune.co/investors/profile/featherlite) — VC Fund, 1 deal together
- [IM Holdings BV](https://shizune.co/investors/profile/im-holdings-bv) — VC Fund, 1 deal together
- [K&K Vision GmbH](https://shizune.co/investors/profile/k-k-vision-gmbh) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [Titan Capital](https://shizune.co/investors/profile/titan-capital) — VC Fund
- [Inflection Point Ventures](https://shizune.co/investors/profile/inflection-point-ventures-d275) — VC Fund
- [Blume Ventures](https://shizune.co/investors/profile/blume-ventures) — VC Fund

## Featured in investor lists
- [Biotech VC Funds in India](https://shizune.co/investors/biotech-vc-funds-india)
- [Life Science Investors in India](https://shizune.co/investors/life-science-investors-india)
- [Life Science VC Funds in India](https://shizune.co/investors/life-science-vc-funds-india)
- [Biotechnology VC Funds in India](https://shizune.co/investors/biotechnology-vc-funds-india)

## FAQ

### What does Acquipharma invest in?

Acquipharma invests primarily in Finance, Medical and Health Care startups, most often at Series A and Series B stage. Most of the 5 investments tracked by Shizune back companies in India. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Acquipharma's check size?

Acquipharma typically joins rounds of $7.5M–$18M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Acquipharma participates in.

### When did Acquipharma last invest?

The most recent investment recorded for Acquipharma closed in Sep 2025. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co